Please assess the completion status of the following clinical trial:

Trial Title: Effects of Bevespi on Ventilation and Gas Exchange Abnormalities in COPD Assessed by 129Xe MRI

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of COPD confirmed by post-bronchodilator spirometry demonstrating (forced expiratory volume at 1 second(FEV1)/forced vital capacity (FVC) \< 0.70 and forced expiratory volume at 1 second (FEV1) in GOLD 2 or 3 stage (30%≤ (forced expiratory volume at 1 second \[FEV1\] \< 80%)~* Willing and able to give informed consent and adhere to visit/protocol schedules~* Women of childbearing potential must have a negative urine pregnancy test~Exclusion Criteria:~* Upper respiratory tract infection within 6 weeks~* Chronic systemic corticosteroid use \> 10 mg/day of prednisone~  * Chronic oxygen use (intermittent or continuous)~ * Previous lung resection surgery or decortication~ * Previous history of pneumothorax~ * Evidence of interstitial, occupational or chronic infectious lung disease by imaging studies~ * History of exposure to occupational or environmental hazards that are known to cause lung diseases~ * For women of child bearing potential, positive pregnancy test~ * Major chronic illnesses which in the judgement of the study physician would interfere with participation in the study~ * Patients who are not willing to withhold COPD inhalers for the run-in period.~    * MRI is contraindicated based on responses to MRI screening questionnaire~   * Subject is pregnant or lactating~   * Respiratory illness of a bacterial or viral etiology within 30 days of MRI~   * Subject has any form of known cardiac arrhythmia~   * Subject does not fit into 129Xe vest coil used for MRI~   * Subject cannot hold his/her breath for 15 seconds~   * Subject deemed unlikely to be able to comply with instructions during imaging

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- single arm (Type: EXPERIMENTAL): glycopyrrolate/formoterol (Bevespi) 2 puffs twice a day taken for two weeks, started after completion of the study XeMRI. A follow up xeMRI occurs at the end of the two weeks of taking the Bevespi in a Pre-post study design.

Based on this trial design, predict the completion outcome and termination type (if applicable).